Why Is Incannex Healthcare Stock Surging Today?
Synopsis
The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.
Incannex Healthcare Inc. (IXHL) on Tuesday announced positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The stock shot up nearly 18% in Tuesday’s pre-market session.
The company said that the results from the trial confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, including on the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.